Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.23.1
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
May 31, 2013
Cash, Cash Equivalents, and Short-Term Investments $ 48,400      
Net Income (Loss) Attributable to Parent (13,183) $ (5,101)    
Retained Earnings (Accumulated Deficit) $ (303,604)   $ (290,421)  
Pieris Pharmaceuticals GmbH [Member]        
Business Acquisition, Percentage of Voting Interests Acquired       100.00%